Updated: April 2, 2026
How Does Tolak Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett

Summarize with AI
How does Tolak (fluorouracil 4% cream) actually destroy actinic keratosis lesions? Here's a plain-English explanation of its mechanism of action and how it heals skin.
Your dermatologist prescribed Tolak to treat your actinic keratosis, and they warned you that your skin is going to look alarming during treatment. But how does a cream actually destroy precancerous cells — and why does that process look so dramatic on your skin? This guide explains the science of how Tolak works, in plain English.
What Is Fluorouracil?
Fluorouracil (5-FU) is the active ingredient in Tolak. It's a synthetic drug that belongs to the antimetabolite class of chemotherapy agents — drugs that interfere with the building blocks of DNA and RNA. Fluorouracil has been used in medicine since 1962, first as an intravenous cancer drug, and later as a topical treatment for precancerous and superficial cancerous skin lesions.
In Tolak, fluorouracil is formulated at 4% concentration in a cream base for once-daily topical application. The cream contains peanut oil and other inactive ingredients that help the drug penetrate and act on the skin lesions.
The Big Picture: What Is Tolak Doing to Your Skin?
When you apply Tolak to actinic keratosis lesions, you're applying a topical chemotherapy agent that preferentially targets rapidly dividing, abnormal cells — the precancerous cells in your actinic keratosis — and stops them from replicating. When those cells can no longer divide, they die. Your immune system then clears away the dead cells, and new, healthy skin cells regrow in their place.
This process — killing, clearing, and regrowth — is visible on your skin as redness, crusting, peeling, and then healing. It looks alarming, but it's the treatment working.
The Detailed Mechanism: How Fluorouracil Blocks Cell Division
Here's the step-by-step science, simplified:
- Fluorouracil enters dividing cells. Because abnormal skin cells in actinic keratosis divide more rapidly than normal skin cells, they absorb fluorouracil more readily.
- It impersonates a DNA building block. Fluorouracil is structurally similar to uracil, a natural component of RNA. Inside the cell, it gets converted into a molecule that the cell tries to use to build new DNA — but it doesn't work correctly.
- It blocks a critical enzyme (thymidylate synthetase). Fluorouracil's active metabolite blocks the enzyme thymidylate synthetase, which is essential for synthesizing thymidine — one of the four building blocks of DNA. Without thymidine, the cell cannot make new DNA.
- Cell division stops — and the cell dies. Without the ability to replicate its DNA, the cell cannot divide. The damaged, abnormal cell dies through a process called apoptosis (programmed cell death).
- Inflammation and clearing occur. As abnormal cells die, your body mounts an inflammatory response — redness, swelling, and crusting — to remove the dead cells. This is what the skin reactions you see during Tolak treatment actually are.
- Healthy skin regrows. After treatment ends and the inflammation resolves (typically within 4 weeks), new, healthy skin cells replace the destroyed precancerous ones.
Why Does Tolak Affect Normal Skin Too?
Fluorouracil is not perfectly selective for abnormal cells — it affects any rapidly dividing cell, including some normal skin cells in the treated area. This is why even the skin around your visible AK lesions becomes red and irritated. In fact, some patients are surprised to find that areas they didn't think had lesions also react to Tolak — this is because Tolak can detect and treat subclinical (invisible) actinic keratosis that wasn't yet visible to the naked eye.
What Role Does DPD Enzyme Play?
The enzyme dihydropyrimidine dehydrogenase (DPD) is responsible for breaking down fluorouracil in the body. In most people, DPD converts fluorouracil into inactive metabolites that are safely eliminated. Patients with DPD deficiency cannot properly break down fluorouracil, which leads to dangerously high blood levels of the drug even from topical application — causing life-threatening systemic toxicity. This is why DPD deficiency is a contraindication to Tolak.
The Bottom Line: Understanding Why Tolak Looks Scary But Works
Understanding how Tolak works makes it easier to stick with the treatment when your skin looks its worst. The redness, crusting, and peeling are your skin's normal inflammatory response to dying abnormal cells — evidence that the drug is working. See our guides on Tolak side effects and what Tolak is used for to learn more.
Frequently Asked Questions
Tolak's active ingredient, fluorouracil, is an antimetabolite that blocks an enzyme called thymidylate synthetase, which is required for DNA synthesis. Without the ability to make DNA, abnormal cells in actinic keratosis lesions cannot divide and die. The resulting inflammation (redness, crusting, peeling) is your body clearing away the dead cells.
Fluorouracil affects any rapidly dividing cells in the treatment area — including subclinical (invisible) actinic keratosis that hasn't yet formed visible lesions. It's common for some patients to see skin reactions in areas that appeared normal before treatment, which actually indicates Tolak is detecting and treating early-stage disease.
Tolak (fluorouracil 4% cream) has limited systemic absorption when applied topically to intact skin as directed. However, in patients with DPD enzyme deficiency, even small amounts of absorbed fluorouracil can accumulate to dangerous levels. In patients with normal DPD function, systemic side effects from topical Tolak are rare.
Most patients begin to notice skin reactions (redness, scaling) within the first 1-2 weeks of applying Tolak — this is an early sign of the drug working. The reaction typically intensifies over the full 4-week treatment period. Healing and visible improvement in lesion clearance occurs in the weeks following treatment completion.
Fluorouracil is the same class of drug used in intravenous chemotherapy, but topical Tolak works locally on the skin rather than systemically throughout the body. The mechanism — blocking DNA synthesis in rapidly dividing cells — is the same, but the concentrations, delivery method, and systemic exposure are very different from IV chemotherapy.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Tolak also looked for:
More about Tolak
35,181 have already found their meds with Medfinder.
Start your search today.





